Full-Time

Analyst – Data Engineer

Posted on 9/9/2026

Deadline 9/15/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

No salary listed

Bengaluru, Karnataka, India

Hybrid

At least three days per week in the office.

Bachelor's, Master's

Category
AI & Machine Learning (1)
Required Skills
LLM
Rust
Microsoft Azure
Python
JavaScript
Airflow
GitHub Actions
ServiceNow
Apache Spark
SQL
MLflow
Data Engineering
Docker
TypeScript
Electronic Health Records (EHR)
Salesforce
Role-based Access Control
Go
DevOps
HIPAA
Snowflake

Get referred to Alexion

See people who can refer or advise you

Requirements
  • A Bachelor’s or Master’s degree in Computer Science, Data Engineering, or a related field, or equivalent experience.
  • Three to six or more years of experience in MLOps, Data Engineering, or ML Platform roles, including deploying machine learning solutions at scale.
  • At least two years of experience building complex data science or large-scale analytics solutions.
  • Proficiency in Python and SQL, with familiarity with TypeScript, JavaScript, Go, or Rust.
  • Experience with test-driven development, continuous integration and continuous delivery pipelines, and code quality standards.
  • Experience with continuous integration and continuous delivery tools such as GitHub Actions or Azure DevOps, Docker, and cloud infrastructure concepts.
  • Hands-on experience with model packaging and serving frameworks such as SageMaker or Databricks MLflow, experiment tracking, and model registry tools.
  • Proficiency with Snowflake, including Snowpark and Snowpark Container Services, distributed processing with Spark, and data orchestration with Airflow.
  • Hands-on experience with AI coding tools such as Claude Code, GitHub Copilot, or Cursor, and Cortex AI or comparable large language model serving platforms.
  • Working understanding of how large language models reason about code and familiarity with prompt engineering as an engineering discipline.
  • Understanding of healthcare data privacy and security, with experience in secrets management, audit controls, and compliance frameworks such as HIPAA, SOC 2, and 21 CFR Part 11.
  • Ability to design systems whose components interact at scale across traditional machine learning infrastructure and agentic artificial intelligence architectures.
Responsibilities
  • Develop and maintain pipelines that transition models from experimentation to production, including packaging, continuous integration and continuous delivery, automated testing, and deployment.
  • Support model serving for patient identification, adherence prediction, Next-Best-Action engines, and competitive intelligence models on Snowflake and Cortex AI.
  • Design robust batch and streaming data workflows integrating specialty pharmacy, hub/patient services program, customer relationship management, syndicated, claims, and Model N data within Snowflake.
  • Define and manage feature sets, data lineage, and reuse to support artificial intelligence and machine learning initiatives across the rare disease portfolio.
  • Ensure the reliability and scalability of machine learning systems by implementing logging, tracing, and alerting.
  • Establish monitoring for model performance, data drift, bias, service health, and data quality across rare disease data feeds.
  • Collaborate with data scientists and commercial stakeholders to decompose complex business workflows into agent-executable workstreams on Cortex AI.
  • Determine which workflow components are best suited for agent execution versus human data science judgment and define the boundaries between them.
  • Design and maintain prompt architectures, agent skills, agent memories, and context injection patterns.
  • Author structured coding instructions that translate commercial analytics requirements into precise agent directives with clear acceptance criteria.
  • Build agentic artificial intelligence systems that detect anomalies in commercial data, generate hypotheses, and push recommended actions to stakeholders and customer relationship management systems.
  • Optimize agent execution for cost efficiency by managing context-window utilization, minimizing token consumption, reducing iteration cycles, and monitoring token economics per workstream.
  • Implement version control, approvals, documentation, and audit trails for datasets, code, models, and agent instructions.
  • Ensure artificial intelligence and machine learning outputs are explainable, auditable, and compliant with HIPAA/PHI, GDPR, FDA promotional regulations, and REMS requirements.
  • Enforce secrets management, role-based access control, network policies, and data protection for agents operating on sensitive healthcare and commercial data.
  • Work with data scientists, commercial analysts, and collaborators across Brand, Market Access, Patient Services, and Field teams to provide frameworks, templates, and guardrails that accelerate analytics delivery.
  • Establish testing frameworks for traditional machine learning models and agent-generated code, including type checking, linting, integration tests, and contract tests.
  • Design validation pipelines with automated quality gates.
  • Develop operational guides, playbooks, and user instructions; coordinate releases with commercial operations and information technology; and maintain runbooks, rollback strategies, and change tickets.
Desired Qualifications
  • Knowledge of pharmaceutical commercial analytics in rare disease or specialty pharma, including healthcare professional and healthcare organization targeting, patient identification, call planning, demand forecasting, specialty pharmacy data, hub/patient services program operations, and omnichannel measurement.
  • Experience with IQVIA datasets such as LAAD, Symphony, and NPA; Veeva CRM; MMIT; Model N; specialty pharmacy dispense data; claims/real-world data; and electronic medical record/electronic health record data in small-population, high-value-per-patient environments.
  • Experience designing multi-agent workflows, agent orchestration patterns, and autonomous systems for enterprise applications.
  • Understanding of Model Context Protocol and agent interoperability frameworks.
  • Experience with high-throughput inference, batch scoring at scale, low-latency application programming interfaces, and horizontal scalability for agent workloads.
  • Experience integrating with Snowflake, Veeva, Salesforce, Microsoft 365, and ServiceNow application programming interfaces.
  • Excellent verbal and written communication skills, including presenting complex findings to technical and non-technical audiences, and a strong orientation toward teamwork in a fast-paced, regulated environment.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old